不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于 CAR 的疗法：超越癌症的免疫医学机遇
英文原题：CAR-based therapies: opportunities for immuno-medicine beyond cancer.
查看英文原题
CAR-based therapies: opportunities for immuno-medicine beyond cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
针对癌症最令人振奋的新疗法之一涉及使用经过工程改造以识别并摧毁癌细胞的自体T细胞。此前无法治疗的B细胞白血病和淋巴瘤患者已被治愈，目前正在努力将这一成功扩展到其他肿瘤。在此，我们讨论近期研究以及旨在将这一方法扩展到肿瘤学之外领域（如心脏代谢疾病、自身免疫、纤维化和衰老）的新兴研究。我们还总结了可能有助于降低成本并提高相关形式免疫治疗可及性的新技术。
展开英文摘要原文
One of the most exciting new therapies for cancer involves the use of autologous T cells that are engineered to recognize and destroy cancerous cells. Patients with previously untreatable B cell leukaemias and lymphomas have been cured, and efforts are underway to extend this success to other tumours.
Here, we discuss recent studies and emerging research aimed to extend this approach beyond oncology in areas such as cardiometabolic disorders, autoimmunity, fibrosis and senescence.
We also summarize new technologies that may help to reduce the cost and increase access to related forms of immunotherapy.
论文信息
- 作者
- Aghajanian H、Rurik JG、Epstein JA
- 第一作者单位
- Department of Cell and Developmental Biology, Penn Cardiovascular Institute and Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.United States
- 通讯作者单位
- Department of Cell and Developmental Biology, Penn Cardiovascular Institute and Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. epsteinj@upenn.edu.United States
- 文献类型
- 美国 NIH 资助研究 · 非美国政府资助研究 · 综述
- 期刊
- Nature metabolism2022 Feb
- 原文标识
- PubMed 35228742 · DOI 10.1038/s42255-022-00537-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →